Multiple Myeloma
Conditions
Keywords
Relapsed and/or Refractory, Relapsed/Refractory Multiple Myeloma, CD38, Anti-CD3, Immunotherapy, monoclonal antibodies, bispecific, T-cell engager
Brief summary
This is a first in human, phase 1, multicenter, open-label study to determine the safety and tolerability of IGM-2644 as a single agent in participants with relapsed and/or refractory MM, for whom standard therapy does not exist, has proven to be ineffective or intolerable, or is considered inappropriate. Dose escalation and dose expansion cohorts will be enrolled to evaluate safety, preliminary efficacy, and further define a RP2D. The total length of the study, from screening of the first participant to the end of the study, is expected to be approximately 60 months.
Detailed description
Patients will be enrolled in two stages: a dose-escalation stage and a dose expansion stage. The escalation stage will investigate single agent IGM-2644 safety and tolerability in patients with relapsed and/or refractory multiple myeloma. The dose expansion cohort(s) will further evaluate safety, PK/PD, and preliminary efficacy of the recommended phase 2 dose (RP2D). IGM-2644 will be administered intravenously (IV).
Interventions
DRUGIGM-2644
IGM-2644 is an engineered, bispecific IgM antibody directed against CD3 and CD38. IGM-2644 is designed to bind to CD38 to selectively target and kill myeloma cancer cells through both T-cell dependent cellular toxicity (TDCC) and complement dependent cytotoxicity (CDC) activities.
Sponsors
IGM Biosciences, Inc.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adults \> 18 years at time of consent * ECOG performance status of 0 or 1 * Relapsed and/or refractory multiple myeloma after ≥ 3 prior lines; Must have failed treatment with an IMiD, PI, and anti-CD38 therapy * Measurable disease per the IMWG response criteria * Adequate marrow and organ function without transfusion or growth factor support within 7 days prior to screening * Willing and able to undergo bone marrow aspirate and biopsy per protocol
Exclusion criteria
* Inability to comply with study and follow-up procedures * History of clinically significant primary amyloidosis, plasma cell leukemia, Waldenstrom macroglobulinemia or myelodysplastic syndrome * Received chemotherapy, biologics, or small molecule therapy within 21 days or 5 half-lives, whichever is shorter * Use of any non-approved or investigational agent ≤ 4 weeks prior to the first dose of study drug. * Received last prior anti-CD38 monoclonal antibody treatment within 28 days before first planned dose of the study drug * Current Grade \> 1 toxicity, with the exception of Grade 2 peripheral neuropathy, alopecia, or toxicities from prior anti-tumor therapy that are considered irreversible * Large-field radiotherapy within 28 days prior to Day 1 (radiation to a single site as concurrent therapy is allowed) * Prior autologous stem cell transplant within 180 days prior to Day 1 * Prior allogeneic stem cell transplant
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To evaluate the safety and tolerability of IGM-2644 in participants with multiple myeloma, including estimation of the maximum tolerated dose (MTD) or maximum administered dose (MAD) | From Dose 1 through 30 days after the last dose of study treatment, approximately 14 months (each cycle is 21 days) | Incidence of treatment-emergent AEs, SAEs, and DLT per NCI CTCAE v5.0 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Clearance (CL) of IGM-2644 | At predefined intervals from Dose 1 through 30 days after the last dose of study treatment, approximately 14 months (each cycle is 21 days) | Clearance (CL) of IGM-2644 |
| Maximum Plasma Concentration (Cmax) of IGM-2644 | At predefined intervals from Dose 1 through 30 days after the last dose of study treatment, approximately 14 months (each cycle is 21 days) | Maximum Plasma Concentration (Cmax) of IGM-2644 as a single agent |
| Half Life (HL) of IGM-2644 | At predefined intervals from Dose 1 through 30 days after the last dose of study treatment, approximately 14 months (each cycle is 21 days) | Half Life (HL) of IGM-2644 as a single agent |
| Area Under the Curve (AUC) of IGM-2644 | At predefined intervals from Dose 1 through 30 days after the last dose of study treatment, approximately 14 months (each cycle is 21 days) | Area Under the Curve (AUC) of IGM-2644 as a single agent |
| Objective Response Rate (ORR) | At predefined intervals from Dose 1 until documented disease progression, total overall study duration approximately 60 months | To assess preliminary efficacy of IGM-2644 as a single agent, defined as the percentage of participants who achieve a confirmed complete response (CR), very good partial response (VGPR), or partial response (PR) per the International Myeloma Working Group (IMWG) |
| Duration of Response (DoR) | At predefined intervals from Dose 1 until documented disease progression, total overall study duration approximately 60 months | For participants who demonstrate a confirmed complete response (CR), very good partial response (VGPR), or partial response (PR), defined as the time from the first documented response to the first documented disease progression or death, whichever occurs first. |
| Progression Free Survival (PFS) | At predefined intervals from Dose 1 until documented disease progression, total overall study duration approximately 60 months | PFS is defined as the time from first dose to the first documented disease progression per IMWG criteria by investigator or death, whichever occurs first. |
| Anti-Drug Antibodies (ADA) Formation | At predefined intervals from Dose 1 through 30 days after the last dose of study treatment, approximately 14 months (each cycle is 21 days) | To evaluate the immunogenicity of IGM-2644 as a single agent |
Countries
United States
Outcome results
None listed